NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston. Terrence West, MBA, the company’s New Business, Virtual CEO has been appointed to the newly created position of Chief Operating Officer, effective immediately, to further drive the growth of NMS-US while continuing to oversee the strategic positioning of NMS-173, its IDH1/IDH2 Inhibitor Asset.
“As we move to the next stages of growth in the Boston area, we felt it was the right time to expand Terrence’s responsibilities, taking advantage of his broad leadership and start-up experience,” stated Lisa Mahnke, M.D., PhD, CEO NMS-US, Board Member and Chief Medical Officer of NMS S.r.l. “He will also continue to implement and negotiate strategies for NMS-173 with potential partners and investors, further supporting our oncology-forward approach.”
“I am very happy to grow my responsibilities within NMS-US while continuing to work with the team at NMS Group,” said Mr. West. “I am looking forward to our continued expansion into the Boston biotech hub, working to bring new oncology therapies to patients.”
Link: Terrence West goes from New Business Virtual CEO-to COO
from NMSGroup
